3/25
04:05 pm
pgen
Precigen Reports Full Year 2025 Financial Results and Business Updates
High
Report
Precigen Reports Full Year 2025 Financial Results and Business Updates
3/19
08:19 am
pgen
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships [Yahoo! Finance]
Low
Report
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships [Yahoo! Finance]
3/12
05:23 pm
pgen
Assessing Precigen (PGEN) Valuation After Recent Share Price Weakness And Conflicting Fair Value Estimates [Yahoo! Finance]
Medium
Report
Assessing Precigen (PGEN) Valuation After Recent Share Price Weakness And Conflicting Fair Value Estimates [Yahoo! Finance]
3/12
06:32 am
pgen
Precigen (PGEN) was upgraded by Zacks Research from "strong sell" to "hold".
Medium
Report
Precigen (PGEN) was upgraded by Zacks Research from "strong sell" to "hold".
3/11
04:05 pm
pgen
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Medium
Report
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
3/5
08:48 am
pgen
Precigen (PGEN) Surged Following the Early Approval of Papziemos [Yahoo! Finance]
Medium
Report
Precigen (PGEN) Surged Following the Early Approval of Papziemos [Yahoo! Finance]
2/11
09:40 am
pgen
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
Medium
Report
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
1/24
06:29 am
pgen
Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/20
08:05 am
pgen
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Low
Report
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
1/12
08:00 am
pgen
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
1/5
05:02 pm
pgen
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
High
Report
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
04:05 pm
pgen
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference